Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
WKEY | WISeKey International Holdings AG | 7.84 | 4.56 | 139.02% | 75,525,572 |
IPHA | Innate Pharma SA | 3.00 | 1.45 | 93.55% | 13,593,143 |
AVL | Direxion Daily AVGO Bull 2X Shares | 33.67 | 11.06 | 48.92% | 658,552 |
LOOP | Loop Industries Inc | 1.8092 | 0.5792 | 47.09% | 82,561,899 |
AVGX | Defiance Daily Target 2X Long AVGO ETF | 31.49 | 10.02 | 46.67% | 3,551,058 |
CGTL | Creative Global Technology Holdings Ltd | 7.10 | 1.98 | 38.71% | 79,554 |
ONDS | Ondas Holdings Inc | 1.405 | 0.385 | 37.75% | 9,390,345 |
SPAI | Safe Pro Group Inc | 4.445 | 1.21 | 37.19% | 933,028 |
VRPX | Virpax Pharmaceuticals Inc | 0.41 | 0.1091 | 36.26% | 9,645,391 |
SNES | SenesTech Inc | 3.96 | 0.96 | 32.00% | 4,807,457 |
TRUG | TruGolf Holdings Inc | 0.6794 | 0.1605 | 30.93% | 141,893,360 |
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) at the recommended Phase 2 dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.
PLYMOUTH MEETING, Pa., Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and accompanying warrants to purchase 10,000,000 shares of its common stock at an exercise price of $3.76 per share of common stock, at a combined public offering price of $3.00 per share of common stock and accompanying warrant. All of the securities in the offering are being sold by INOVIO. ...
Safe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, today announced that its Artificial Intelligence subsidiary, Safe Pro AI, has introduced SpotlightAI™ ONSITE its latest real-time automatic mine detection software designed for use with virtually any drone. The Microsoft Windows-based AI-powered drone imagery analysis software is currently undergoing real-world testing in Ukraine.
New Era Helium, Inc. (Nasdaq:NEHC) (“NEH,” “New Era Helium” or the “Company”), an exploration and production (E&P) company sourcing helium produced in association with natural gas reserves within the Permian Basin, is pleased to announce significant progress on its 50/50 joint venture (“JV”) with Sharon AI, Inc. (“Sharon AI”), a High-Performance Computing business specializing in Artificial Intelligence, Cloud GPU Compute Infrastructure, and Cloud Storage.
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
CGAC | Code Green Apparel Corp | 138 | |
RDAR | Raadr Inc | 49 | |
ASII | Accredited Solutions Inc | 47 | |
4 | AMRN | Amarin Corp Plc | 50 |
5 | AZRH | Azure Holding Group Corp | 22 |
6 | NSAV | NSAV Holding Inc | 32 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 102,228.04 | 771.51 | 0.76% | 2.02T | 5,549,196,312 |
ETH | Ethereum | 3,920.16 | 9.86 | 0.25% | 471.86B | 3,290,579,367 |
XRP | Ripple | 2.46 | 0.040 | 1.65% | 138.58B | 2,183,567,570 |
USDT | Tether USD | 1.00 | 0.00 | 0.00% | 119.66B | 902,099,357 |
BNB | Binance Coin | 728.68 | 2.56 | 0.35% | 115.07B | 505,248,840 |
SOL | Solana | 226.40 | 1.49 | 0.66% | 105.93B | 1,267,266,975 |
DOGE | Dogecoin | 0.4101 | 0.00121 | 0.30% | 59.97B | 1,426,747,913 |
ADA | Cardano | 1.12 | 0.00 | 0.00% | 39.98B | 398,549,078 |
STETH | stETH | 3,915.08 | 9.08 | 0.23% | 38.43B | 9,841,169 |
USDC | USD Coin | 0.9999 | 0.00 | 0.00% | 35.55B | 1,264,603,588 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions